The Guardian Business Bacaan 6 menit

Four takeaways from Anthropic’s potentially record-breaking stock market filing

Four takeaways from Anthropic’s potentially record-breaking stock market filing
The 92-page document released on Monday talks about Anthropic’s explosive growth and the risks AI has brought to the business. Photograph: Kim Kyung-Hoon/Reuters

1. Explosive and expensive growthHere’s what you need to know: Anthropic is making a lot of money. It’s also losing a lot of it. The five-year-old firm has been valued between $1.5 and $2tn by some investors but did not list a target valuation in its S-1. Founded in 2021, the company has seen explosive growth every year of its existence.Anthropic brought in $16.3bn in revenue and lost $80bn in just the first half of 2026, though much of that was due to a $72.4bn one-off charge. In 2025, the company brought in $4.585bn and lost roughly $33.9bn, per the filing.Column chart showing quarterly filings from Anthropic from Q1 2025 to Q2 2026. While revenues are increasing quarter over quarter, net losses are increasing at a faster rate.Securing computing power accounts for the vast majority of Anthropic’s costs. The company spent nearly $9bn on AI infrastructure in the first half of this year, up from $2.3bn in the same period last year.Anthropic, unlike OpenAI, has made it clear that its customers are largely other businesses. “Frontier AI is most valuable in real-world settings, as deployment across enterprises is where economic impact is greatest,” the company executives wrote in the filing.The company said its top five customers account for 25% of its business – which makes it risky business.

2. ‘A country of geniuses in a datacenter’Anthropic says there is considerable potential for AI to reach levels of intelligence that would be akin to what its executives called “‘a country of geniuses in a datacenter’ – millions of virtual agents with the ability to revolutionize every area of human endeavor: software, physics, math, biology, medicine, finance, economics, commerce, robotics, military and intelligence capabilities”. The company’s executives claim they have also made biological discoveries with Claude, including a “molecular machine” that has the “potential to be developed into a novel biotechnology tool”. One purported use case: gene editing.

Lanjutkan membaca di The Guardian Business

Kutipan awal dari The Guardian Business, ditulis oleh Johana Bhuiyan. Hak cipta artikel milik penerbit.

Berita lainnya untuk Anda